Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Eye Condition a ‘Very Rare’ Side Effect of Semaglutide, EMA Says

News Daily News

Eye Condition a ‘Very Rare’ Side Effect of Semaglutide, EMA Says

June 06, 2025

EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts

News Daily News

EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts

April 12, 2024

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

News Daily News

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

January 12, 2024

GLP-1 Meds Linked to 265 Reports to FDA of Suicidal Ideation: Reuters

News Daily News

GLP-1 Meds Linked to 265 Reports to FDA of Suicidal Ideation: Reuters

September 28, 2023

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

News Daily News

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Michael O'Riordan

September 15, 2023

FDA: Obesity Drug Lorcaserin Exits US Market Over Cancer Concerns

News Daily News

FDA: Obesity Drug Lorcaserin Exits US Market Over Cancer Concerns

February 14, 2020

News Daily News

CV Safety Trial for Lorcaserin Picks Up Cancer Signal: FDA

January 14, 2020

TCTMD’s Top 10 Most Popular Stories for January 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

January 31, 2019

News Daily News

Experimental FAAH Inhibitors Do Not Pose Safety Risk, FDA Concludes

Michael O'Riordan

August 12, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.